basically if breakthroughs designation is obtained (assuming this has been applied for soon if not already) then P2 will be a pathway to approval. In that instance the trial will need to be in the US.
If funding is x3-4 times Australia say a cool $30m then there could be partnership or Cr sooner than expected. My view is the catalyst is breakthrough designation, will force Race’s hand. Until we see that I think no change in Trials being in Australia.
@johndprent is this also your view?
RAC media coverage, page-1198
-
- There are more pages in this discussion • 1,088 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.000(0.00%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.95 | $1.95 | $1.84 | $647.3K | 344.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3300 | $1.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.94 | 5654 | 2 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |